OBI Pharma has entered a collaboration and license agreement with Novartis to develop antibody-drug conjugates using OBI's platform technologies and novel payloads. OBI will receive $30 million upfront and is eligible for development, regulatory and commercial milestone payments, bringing the total potential deal value to more than $2 billion, plus tiered royalties on net sales of licensed products.
Novartis will receive exclusive worldwide rights to OBI's related patents and know-how for selected Novartis payload classes. OBI will evaluate new linker approaches with those payloads, while Novartis will have an option to expand the agreement to additional payload classes.
The collaboration involves technologies within OBI's Obrion ADC platform, including GlycOBI, EndoSymeOBI, HYPrOBI and GlycOBI DUO. GlycOBI uses glycan-based conjugation and is compatible with a range of antibodies, linkers and payloads, supporting different drug-to-antibody ratios.
EndoSymeOBI provides dual-function enzymatic technology, while HYPrOBI supplies hydrophilic, stable linker technology used in producing site-specific, homogeneous ADCs under GMP conditions. GlycOBI DUO extends the platform to ADC formats that include dual-payload constructs.
Shiva Malek, global head of oncology, Biomedical Research at Novartis, said the collaboration forms part of the company's oncology ADC strategy. OBI Acting Chief Executive Officer Ya-Chi Chen said the agreement combines the company's ADC expertise with Novartis's development and commercialization capabilities.
OBI is a clinical-stage oncology company established in 2002 and headquartered in Taiwan, with operations in the United States and Australia. Its work includes cancer therapeutics and the development of proprietary antibody-drug conjugate technologies.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!